Related Content
Search Google Scholar for:
More Information
Related Jobs from ScienceCareers
|
|
Science 17 November 1995: Vol. 270. no. 5239, pp. 1194 - 1197 DOI: 10.1126/science.270.5239.1194
|
|
Reports
Inhibitors of HIV Nucleocapsid Protein Zinc Fingers as Candidates
for the Treatment of AIDS
William G. Rice (1),
Jeffrey G. Supko,
Louis Malspeis,
Robert W. Buckheit Jr.,
David Clanton,
Ming Bu,
Lisa Graham,
Catherine A. Schaeffer,
Jim A. Turpin,
John Domagala,
Rocco Gogliotti,
John P. Bader,
Susan M. Halliday,
Lori Coren,
Raymond C. Sowder II,
Larry O. Arthur,
Louis E. Henderson
Strategies for the treatment of human immunodeficiency virus-type
1 (HIV-1) infection must contend with the obstacle of drug resistance.
HIV-1 nucleocapsid protein zinc fingers are prime antiviral targets
because they are mutationally intolerant and are required both for
acute infection and virion assembly. Nontoxic disulfide-substituted
benzamides were identified that attack the zinc fingers, inactivate
cell-free virions, inhibit acute and chronic infections, and exhibit
broad antiretroviral activity. The compounds were highly synergistic
with other antiviral agents, and resistant mutants have not been
detected. Zinc finger-reactive compounds may offer an anti-HIV
strategy that restricts drug-resistance development.
W. G. Rice, M. Bu, L. Graham, C. A. Schaeffer, J. A. Turpin,
Laboratory of Antiviral Drug Mechanisms, PRI/DynCorp, National Cancer
Institute-Frederick Cancer Research and Development Center, Frederick,
MD 21702, USA.
J. G. Supko and L. Malspeis, Laboratory of Pharmaceutical Chemistry,
Developmental Therapeutics Program, Division of Cancer Treatment,
National Cancer Institute, Frederick, MD 21701-8527, USA.
R. W. Buckheit Jr. and S. M. Halliday, Virology Research Group,
Southern Research Institute-Frederick Research Center, Frederick, MD
21701, USA.
D. Clanton, Anti-AIDS Virus Drug Screening Laboratory, PRI/DynCorp,
National Cancer Institute-Frederick Cancer Research and Development
Center, Frederick, MD 21702, USA.
J. Domagala and R. Gogliotti, Chemistry Department, Parke-Davis
Pharmaceutical Research Division of Warner-Lambert Company, Ann Arbor,
MI 48105, USA.
J. P. Bader, Antiviral Evaluations Branch, Developmental Therapeutics
Program, Division of Cancer Treatment, National Cancer Institute,
Bethesda, MD 20892, USA.
L. Coren, R. C. Sowder II, L. O. Arthur, L. E. Henderson, AIDS Vaccine
Program, PRI/DynCorp, National Cancer Institute-Frederick Cancer
Research and Development Center, Frederick, MD 21702, USA.
(1) To whom correspondence should be addressed.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- Human Immunodeficiency Virus Type 1 Nucleocapsid Inhibitors Impede trans Infection in Cellular and Explant Models and Protect Nonhuman Primates from Infection.
- G. S. Wallace, C. Cheng-Mayer, M. L. Schito, P. Fletcher, L. M. Miller Jenkins, R. Hayashi, A. R. Neurath, E. Appella, and R. J. Shattock (2009)
J. Virol.
83, 9175-9182
| Abstract »
| Full Text »
| PDF »
- Nucleocapsid mutations turn HIV-1 into a DNA-containing virus.
- L. Houzet, Z. Morichaud, L. Didierlaurent, D. Muriaux, J.-L. Darlix, and M. Mougel (2008)
Nucleic Acids Res.
36, 2311-2319
| Abstract »
| Full Text »
| PDF »
- Development of a Cell-Based Assay Probing the Specific Interaction between the Human Immunodeficiency Virus Type 1 Nucleocapsid and Psi RNA In Vivo.
- S. I. Jang, Y. H. Kim, S. Y. Paik, and J. C. You (2007)
J. Virol.
81, 6151-6155
| Abstract »
| Full Text »
| PDF »
- Methylisothiazolinone, A Neurotoxic Biocide, Disrupts the Association of Src Family Tyrosine Kinases with Focal Adhesion Kinase in Developing Cortical Neurons.
- K. He, J. Huang, C. F. Lagenaur, and E. Aizenman (2006)
J. Pharmacol. Exp. Ther.
317, 1320-1329
| Abstract »
| Full Text »
| PDF »
- Inhibitory effects of archetypical nucleic acid ligands on the interactions of HIV-1 nucleocapsid protein with elements of {Psi}-RNA.
- K. B. Turner, N. A. Hagan, and D. Fabris (2006)
Nucleic Acids Res.
34, 1305-1316
| Abstract »
| Full Text »
| PDF »
- Inactivation of Retroviruses with Preservation of Structural Integrity by Targeting the Hydrophobic Domain of the Viral Envelope.
- Y. Raviv, M. Viard, J. W Bess Jr., E. Chertova, and R. Blumenthal (2005)
J. Virol.
79, 12394-12400
| Abstract »
| Full Text »
| PDF »
- Elimination of Retroviral Infectivity by N-Ethylmaleimide with Preservation of Functional Envelope Glycoproteins.
- D. R. Morcock, J. A. Thomas, T. D. Gagliardi, R. J. Gorelick, J. D. Roser, E. N. Chertova, J. W. Bess Jr., D. E. Ott, Q. J. Sattentau, I. Frank, et al. (2005)
J. Virol.
79, 1533-1542
| Abstract »
| Full Text »
| PDF »
- Inhibition of Invasion and Angiogenesis by Zinc-Chelating Agent Disulfiram.
- S.-G. Shian, Y.-R. Kao, F. Y.-H. Wu, and C.-W. Wu (2003)
Mol. Pharmacol.
64, 1076-1084
| Abstract »
| Full Text »
| PDF »
- G-quartets direct assembly of HIV-1 nucleocapsid protein along single-stranded DNA.
- S. Lyonnais, R. J. Gorelick, J.-L. Mergny, E. Le Cam, and G. Mirambeau (2003)
Nucleic Acids Res.
31, 5754-5763
| Abstract »
| Full Text »
| PDF »
- Evidence for the Differential Effects of Nucleocapsid Protein on Strand Transfer in Various Regions of the HIV Genome.
- S. S. Derebail, M. J. Heath, and J. J. DeStefano (2003)
J. Biol. Chem.
278, 15702-15712
| Abstract »
| Full Text »
| PDF »
- Reversal by Dithiothreitol Treatment of the Block in Murine Leukemia Virus Maturation Induced by Disulfide Cross-Linking.
- S. Campbell, M. Oshima, J. Mirro, K. Nagashima, and A. Rein (2002)
J. Virol.
76, 10050-10055
| Abstract »
| Full Text »
| PDF »
- Human Immunodeficiency Virus and AIDS: Insights from Animal Lentiviruses.
- R. J. Miller, J. S. Cairns, S. Bridges, and N. Sarver (2000)
J. Virol.
74, 7187-7195
| Full Text »
- Identification of a Key Target Sequence To Block Human Immunodeficiency Virus Type 1 Replication within the gag-pol Transframe Domain.
- S. Sei, Q.-e. Yang, D. O'Neill, K. Yoshimura, K. Nagashima, and H. Mitsuya (2000)
J. Virol.
74, 4621-4633
| Abstract »
| Full Text »
- Inactivation of HIV-1 Nucleocapsid Protein P7 by Pyridinioalkanoyl Thioesters. CHARACTERIZATION OF REACTION PRODUCTS AND PROPOSED MECHANISM OF ACTION.
- V. Basrur, Y. Song, S. J. Mazur, Y. Higashimoto, J. A. Turpin, W. G. Rice, J. K. Inman, and E. Appella (2000)
J. Biol. Chem.
275, 14890-14897
| Abstract »
| Full Text »
| PDF »
- Zinc-Altered Immune Function and Cytokine Production.
- L. Rink and H. Kirchner (2000)
J. Nutr.
130, 1407S-1411
| Abstract »
| Full Text »
- The Function of Zinc Metallothionein: A Link between Cellular Zinc and Redox State.
- W. Maret (2000)
J. Nutr.
130, 1455S-1458
| Abstract »
| Full Text »
- Nucleic Acid Binding Properties of the Simian Immunodeficiency Virus Nucleocapsid Protein NCp8.
- M. A. Urbaneja, C. F. McGrath, B. P. Kane, L. E. Henderson, and J. R. Casas-Finet (2000)
J. Biol. Chem.
275, 10394-10404
| Abstract »
| Full Text »
| PDF »
- Multiple Effects of an Anti-Human Immunodeficiency Virus Nucleocapsid Inhibitor on Virus Morphology and Replication.
- L. Berthoux, C. Péchoux, and J.-L. Darlix (1999)
J. Virol.
73, 10000-10009
| Abstract »
| Full Text »
- Human Immunodeficiency Virus Type 1 Gag Polyprotein Multimerization Requires the Nucleocapsid Domain and RNA and Is Promoted by the Capsid-Dimer Interface and the Basic Region of Matrix Protein.
- M. T. Burniston, A. Cimarelli, J. Colgan, S. P. Curtis, and J. Luban (1999)
J. Virol.
73, 8527-8540
| Abstract »
| Full Text »
| PDF »
- Potential Drugs Against Cervical Cancer: Zinc-Ejecting Inhibitors of the Human Papillomavirus Type 16 E6 Oncoprotein.
- W. Beerheide, H.-U. Bernard, Y.-J. Tan, A. Ganesan, W. G. Rice, and A. E. Ting (1999)
J Natl Cancer Inst
91, 1211-1220
| Abstract »
| Full Text »
| PDF »
- A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity.
- S. Druillennec, C. Z. Dong, S. Escaich, N. Gresh, A. Bousseau, B. P. Roques, and M. C. Fournie-Zaluski (1999)
PNAS
96, 4886-4891
| Abstract »
| Full Text »
| PDF »
- The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein.
- M. E. Garber, P. Wei, V. N. KewalRamani, T. P. Mayall, C. H. Herrmann, A. P. Rice, D. R. Littman, and K. A. Jones (1998)
Genes & Dev.
12, 3512-3527
| Abstract »
| Full Text »
- Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Proteins.
- J. L. Rossio, M. T. Esser, K. Suryanarayana, D. K. Schneider, J. W. Bess Jr., G. M. Vasquez, T. A. Wiltrout, E. Chertova, M. K. Grimes, Q. Sattentau, et al. (1998)
J. Virol.
72, 7992-8001
| Abstract »
| Full Text »
| PDF »
- Actinomycin D Inhibits Human Immunodeficiency Virus Type 1 Minus-Strand Transfer in In Vitro and Endogenous Reverse Transcriptase Assays.
- J. Guo, T. Wu, J. Bess, L. E. Henderson, and J. G. Levin (1998)
J. Virol.
72, 6716-6724
| Abstract »
| Full Text »
| PDF »
- A cobalt complex that selectively disrupts the structure and function of zinc fingers.
- A. Y. Louie and T. J. Meade (1998)
PNAS
95, 6663-6668
| Abstract »
| Full Text »
| PDF »
- Efficacies of Zinc-Finger-Active Drugs against Giardia lamblia.
- T. Nash and W. G. Rice (1998)
Antimicrob. Agents Chemother.
42, 1488-1492
| Abstract »
| Full Text »
- Inhibition of Acute-, Latent-, and Chronic-Phase Human Immunodeficiency Virus Type 1 (HIV-1) Replication by a Bistriazoloacridone Analog That Selectively Inhibits HIV-1 Transcription.
- J. A. Turpin, R. W. Buckheit Jr., D. Derse, M. Hollingshead, K. Williamson, C. Palamone, M. C. Osterling, S. A. Hill, L. Graham, C. A. Schaeffer, et al. (1998)
Antimicrob. Agents Chemother.
42, 487-494
| Abstract »
| Full Text »
- Structure of the HIV-1 Nucleocapsid Protein Bound to the SL3
-RNA Recognition Element.
- R. N. De Guzman, Z. R. Wu, C. C. Stalling, L. Pappalardo, P. N. Borer, and M. F. Summers (1998)
Science
279, 384-388
| Abstract »
| Full Text »
|
|